HC Wainwright & Co. Reiterates Buy on Protagonist Therapeutics, Maintains $38 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Protagonist Therapeutics (NASDAQ:PTGX) and maintained a $38 price target.
June 14, 2024 | 5:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Protagonist Therapeutics and maintained a $38 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and the maintenance of a $38 price target by a reputable analyst suggests positive sentiment and confidence in Protagonist Therapeutics' future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100